BSE · 524572
Pharmaids Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Shareholding
As of 2026-06-30
- Promoter32.99%
- Public67.01%
8,632 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.58× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #30 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,429 Cr | 83.11 | 22.12 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹47,982 Cr | 41.88 | 4.64 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,742 Cr | 38.54 | 9.66 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹29,437 Cr | 102.14 | 22.82 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹19,737 Cr | 29.67 | 5.85 | 17.88% | 29.09% |
| Shilpa Medicare Ltd. | ₹18,744 Cr | 65.91 | 7.23 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹18,164 Cr | 27.65 | 4.65 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹14,488 Cr | 28.04 | 4.78 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,344 Cr | 53.33 | 6.15 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,459 Cr | 51.12 | 6.93 | 12.36% | 18.59% |
| Pharmaids Pharmaceuticals Ltd.(this company) | ₹103 Cr | — | 2.2 | -29.76% | -18.15% |
AI analysis
AI-generated · google/gemini-2.5-flashPharmaids Pharmaceuticals Ltd. (524572) has a market capitalization of Rs 112 Cr. The company reported a profit margin of -42.04% and an EPS of 0. The debt-to-equity ratio stands at 0.36. As of June 30, 2026, promoter shareholding was 32.99%, with public shareholding at 67.01%.
Positives
- +The debt-to-equity ratio is 0.36, indicating relatively lower leverage.
- +The book value per share is Rs 13.51.
Negatives
- −The company reported an annual net loss of Rs 10.78 Cr in March 2025 and a quarterly net loss of Rs 1.81 Cr in March 2026.
- −The profit margin is significantly negative at -42.04%.
- −Return on equity (ROE) is -29.76% and return on capital employed (ROCE) is -20.97%.
- −The company has been placed under LT-ASM surveillance, specifically ASM Stage 1.
- −The earnings per share (EPS) is 0.
Financial performance
The company reported annual revenue of Rs 19.55 Cr in March 2025, with a net loss of Rs 10.78 Cr for the same period. Quarterly results for March 2026 showed revenue of Rs 7.18 Cr and a net loss of Rs 1.81 Cr. The EBITDA for March 2026 was -0.72.
Profitability & returns
Pharmaids Pharmaceuticals Ltd. experienced negative profitability metrics. The Roe was -29.76% and Roce was -20.97%. The company reported a negative profit margin of -42.04%, indicating that it operated at a loss relative to its revenue. The EPS as of the latest available data is 0.
Balance sheet
The book value per share is Rs 13.51. The company maintains a debt-to-equity ratio of 0.36. This indicates the proportion of debt used to finance its assets relative to shareholder equity.
Ownership & pledges
As of June 30, 2026, promoters held 32.99% of the company's shares. Public shareholding was 67.01%. There were no shares pledged by the promoters. Over the last few years, the number of shareholders has increased from 4618 in March 2018 to 8632 in June 2026.
Regulatory & surveillance
Pharmaids Pharmaceuticals Ltd. is currently under LT-ASM surveillance, specifically categorized under ASM Stage 1. This indicates that the stock has met certain criteria that warrant closer monitoring by regulatory bodies.
Data as of — price: 2026-09-18 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Pharmaids Pharmaceuticals Ltd.share price & fundamentals